Vaxxas raises $23M for needle-free drug delivery tech - Mass Device

Vaxxas’ spot comes successful a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]

Vaxxas announced contiguous that it completed a financing circular that brings successful $23 cardinal (A$34 million) successful caller funds.

Existing investors OneVentures and UniQuest led the round. New investors, including members of the Vaxxas committee and absorption team, on with idiosyncratic investors, participated. The institution earmarked proceeds to beforehand its objective programs, including its needle-free COVID-19 vaccine candidate.

Other imaginable uses see the installation of the company’s archetypal manufacturing lines. These would connection the capableness to enactment Vaxxas’ archetypal products done late-stage objective studies and aboriginal commercialized production.

Get the afloat communicative astatine our sister site, Drug Delivery Business News.